R
R A Tupker
Publications - 7
Citations - 1343
R A Tupker is an academic researcher. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 2, co-authored 2 publications receiving 1293 citations.
Papers
More filters
Journal ArticleDOI
Guidelines for transepidermal water loss (TEWL) measurement. A report from the Standardization Group of the European Society of Contact Dermatitis.
TL;DR: The Evaporimeter EPI (ServoMed) is reviewed, start‐up and use is described, and guidelines for good laboratory practice given.
Journal ArticleDOI
Guidelines on sodium lauryl sulfate (SLS) exposure tests. A report from the Standardization Group of the European Society of Contact Dermatitis.
TL;DR: This report reviews the clinical and hisiopathological reactions caused by sodium lauryl sulfate (SLS), and the non‐invasive methods that can characterize these reactions, and proposes 2 categories, namely susceptibility testing and provocative testing, tailored to the aim with which the study is performed.
Journal ArticleDOI
Drug Survival, Safety, and Effectiveness of Biologics in Older Patients with Psoriasis: A Comparison with Younger Patients—A BioCAPTURE Registry Study
Elke L M ter Haar,Sarah E Thomas,Juul M. P. A. van den Reek,M.E. Otero,M. D. Njoo,P.M. Ossenkoppele,Else N. Kop,Sharon Dodemont,J.E.M. Körver,A.L.A. Kuijpers,R. J. Lindhout,R A Tupker,J.M. Mommers,M.A.M. Berends,M.I.A. Koetsier,Marjolein S. de Bruin-Weller,M.B. Visch,W.P. Arnold,P.P.M. van Lümig,M.M. Kleinpenning,Satish F K Lubeek,Elke M G J de Jong +21 more
TL;DR: In this paper , the authors used the Charlson Comorbidity Index (CCI) to measure comorbid disease status, and all adverse events (AEs) that led to treatment discontinuation were classified according to the Medical Dictionary for Regulatory Activities (MedDRA) classification.
Journal ArticleDOI
Successful tapering of dupilumab in atopic dermatitis patients with low disease activity: a large pragmatic daily practice study from the BioDay registry.
Lotte S. Spekhorst,Celeste Mirte Boesjes,Laura Loman,Nicolaas P.A. Zuithoff,Daphne S. Bakker,Esme I. Kamphuis,Marijke Kamsteeg,Inge Haeck,A. J. Oosting,Paula van Lumig,A. M. T. van Lynden-van Nes,R A Tupker,Annebeth E. Flinterman,F. M. Garritsen,Wouter R.H. Touwslager,Marjolein S. de Bruin-Weller,Marielouise Schuttelaar,Marlies de Graaf +17 more
TL;DR: In this article , a prospective multicenter study included adult AD patients, participating in the BioDay registry, treated with dupilumab for ≥ 1.3 years, and the estimated cost saving was 3,977,033.98 EUR for 401 patients.
Journal ArticleDOI
Direct Comparison of Real-world Effectiveness of Biologics for Psoriasis using Absolute and Relative Psoriasis Area and Severity Index Scores in a Prospective Multicentre Cohort
M. van Muijen,Sarah E Thomas,Hans Groenewoud,M.E. Otero,P.M. Ossenkoppele,M. D. Njoo,Sharon Dodemont,Else N. Kop,M.J. Berends,M.I.A. Koetsier,J.M. Mommers,J.E.M. Körver,R A Tupker,Marjolein S. de Bruin-Weller,L. Weppner‐Parren,Bas J M Peters,M.M. Kleinpenning,A.L.A. Kuijpers,W.P. Arnold,Paula P. M. van Lümig,Juul M. P. A. van den Reek,Elke M G J de Jong +21 more
TL;DR: Patients treated with adalimumab, ustekinumab, secukinumAB, ixekizumab or guselkumab all had a significantly lower mean PASI after 12 months compared with etanercept, and significantly higher overall odds of reaching PASi90 than those treated with etAnercept.